François Martelet

François Martelet brings over 20 years of biopharma experience and a proven track record of shaping and developing businesses to deliver returns. He has broad experience in both large and small companies, deep knowledge of commercialisation and has proven managerial capabilities

François is currently CEO of NetScientific plc, he previously served as senior advisor to the CEO and Interim SVP at Stallergenes SA where he was responsible for international commercial strategies. During this period, sales revenues grew by 20+% and various new products were launched, including Oralair®, into ex-US markets. Before this, he was CEO at Topotarget A/S, a publicly traded European biotech company specialised in oncology therapeutics which he successfully transformed from a research based organisation into a late-stage clinical development company ready for a European exit.

Prior to this, François served as CEO of Avax Technologies Inc., a US biotech company specialised in therapeutic oncology vaccines. He has also held senior level commercial positions at Merck & Co, Inc. (VP & Global Franchise Head-Oncology), Novartis Pharma (SVP & Head of Central & Eastern Europe, Middle East and Africa), Schering-Plough and Eli Lilly.

François gained a Doctorate in Medicine and a Master's Degree in Business from Dijon University, and holds a Degree in Legal Medicine from R. Descartes University School of Medicine, Paris. He is also a graduate of the Advanced General Management Program at INSEAD.

François Martelet's awards include the Pasteur Institute medal (1989) and the Knight of the French National Order Merit (2011).

François Martelet

Chairman
François Martelet
Dr David Ribeiro

Dr David Ribeiro

CEO
Dr Ribeiro has extensive experience in commercialising products within chronic diseases, having previously held senior management roles at Solvay Healthcare, Encysive Pharmaceuticals and Pfizer.
Read More
Brian Walker

Brian Walker

CSO
Professor Walker has over 30 years experience in the design & synthesis of “Protease-Tags” for the identification and validation of protease targets of biomedical and
Read More
Ian Postlethwaite

Ian Postlethwaite

Non-executive Director
Ian Postlethwaite brings over 14 years of biopharma experience and a proven track record of driving revenue growth and funding development programs. He has broad
Read More
David Moore

David Moore

Head of Spin Outs & Investments, QUBIS Ltd.
David is Investment Manager with QUBIS Ltd, the early stage investment fund responsible for the commercialisation of technology from The Queen’s University of Belfast.
Read More
Lorraine Martin

Lorraine Martin

Non-executive Director
Dr Lorraine Martin is a co-founder of ProAxsis Ltd. and a Senior Lecturer in Molecular Pharmaceutics within the School of Pharmacy, Queen’s University Belfast.
Read More
Ernest Schneider

Ernest Schneider

Non-executive Director
Ernest Schneider is a solicitor, patent & trade mark attorney and accredited mediator. He is the Commercial-Legal Director and Company Secretary of NetScientific plc and
Read More